You have full text access to this OnlineOpen article

How can we predict lymphorrhoea and clinically significant lymphocoeles after radical prostatectomy and pelvic lymphadenectomy? Clinical implications

  1. Umberto Capitanio,
  2. Federico Pellucchi,
  3. Andrea Gallina,
  4. Alberto Briganti,
  5. Nazareno Suardi,
  6. Andrea Salonia,
  7. Firas Abdollah,
  8. Ettore Di Trapani,
  9. Claudio Jeldres,
  10. Andrea Cestari,
  11. Pierre I. Karakiewicz,
  12. Francesco Montorsi

Article first published online: 29 SEP 2010

DOI: 10.1111/j.1464-410X.2010.09580.x

Issue

BJU International

BJU International

Volume 107, Issue 7, pages 1095–1101, April 2011

Additional Information

How to Cite

Capitanio, U., Pellucchi, F., Gallina, A., Briganti, A., Suardi, N., Salonia, A., Abdollah, F., Di Trapani, E., Jeldres, C., Cestari, A., Karakiewicz, P. I. and Montorsi, F. (2011), How can we predict lymphorrhoea and clinically significant lymphocoeles after radical prostatectomy and pelvic lymphadenectomy? Clinical implications. BJU International, 107: 1095–1101. doi: 10.1111/j.1464-410X.2010.09580.x

Author Information

  1. Department of Urology, University Vita–Salute, San Raffaele Hospital, Milan, Italy, *Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada

*Umberto Capitanio, University Vita-Salute San Raffaele, Via Olgettina 60, 20132, Milan, Italy. e-mail: capitanio.umberto@hsr.it

Publication History

  1. Issue published online: 25 MAR 2011
  2. Article first published online: 29 SEP 2010
  3. Accepted for publication 22 April 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (327K)

REFERENCES

  • 1
    Heidenreich A, Aus G, Bolla M et al. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68–80
  • 2
    Jeldres C, Suardi N, Perrotte P et al. Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. Can Urol Assoc J 2009; 3: 13–21
  • 3
    Capitanio U, Scattoni V, Freschi M et al. Radical prostatectomy for incidental (stage T1a–T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. Eur Urol 2008; 54: 118–25
  • 4
    Yossepowitch O, Eggener SE, Serio AM et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol 2008; 53: 950–9
  • 5
    Briganti A, Chun FK, Salonia A et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006; 50: 1006–13
  • 6
    Thalmann GN. Positive lymph nodes at lymphadenectomy for prostate cancer: where do we set the tiller? Eur Urol 2009; 55: 271–4
  • 7
    Briganti A, Blute ML, Eastham JH et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009; 55: 1251–65
  • 8
    Briganti A, Chun FK, Karakiewicz PI, Rigatti P, Montorsi F. Is node-positive prostate cancer always a systemic disease? Eur Urol 2008; 54: 243–6
  • 9
    Naselli A, Andreatta R, Introini C, Fontana V, Puppo P. Predictors of symptomatic lymphocele after lymph node excision and radical prostatectomy. Urology 2009; 75: 630–5
  • 10
    Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002; 168: 514–8
  • 11
    Stone NN, Stock RG, Unger P. Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. J Urol 1997; 158: 1891–4
  • 12
    Paul DB, Loening SA, Narayana AS, Culp DA. Morbidity from pelvic lymphadenectomy in staging carcinoma of the prostate. J Urol 1983; 129: 1141–4
  • 13
    Clark T, Parekh DJ, Cookson MS et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 2003; 169: 145–8
  • 14
    Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008; 54: 344–52
  • 15
    Breyer BN, Greene KL, Dall’Era MA, Davies BJ, Kane CJ. Pelvic lymphadenectomy in prostate cancer. Prostate Cancer Prostatic Dis 2008; 11: 320–4
  • 16
    Studer UE. Should patients with prostate cancer and a risk of nodal metastasis >1% undergo standard or limited PLND? Nat Clin Pract Urol 2008; 5: 10–1
  • 17
    Allaf ME, Partin AW, Carter HB. The importance of pelvic lymph node dissection in men with clinically localized prostate cancer. Rev Urol 2006; 8: 112–9
  • 18
    Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Is pelvic lymph node dissection necessary in patients with a serum PSA <10 ng/mL undergoing radical prostatectomy for prostate cancer? Eur Urol 2006; 50: 272–9
  • 19
    Briganti A, Capitanio U, Chun FK et al. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Eur Urol 2008; 54: 794–802
  • 20
    Mattei A, Fuechsel FG, Bhatta Dhar N et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 2008; 53: 118–25
  • 21
    Nichter LS, Morgan RF, Dufresne CR, Lambruschi P, Edgerton MT. Rapid management of persistent seromas by sclerotherapy. Ann Plast Surg 1983; 11: 233–6
  • 22
    Aitken DR, Hunsaker R, James AG. Prevention of seromas following mastectomy and axillary dissection. Surg Gynecol Obstet 1984; 158: 327–30
  • 23
    Kulber DA, Bacilious N, Peters ED, Gayle LB, Hoffman L. The use of fibrin sealant in the prevention of seromas. Plast Reconstr Surg 1997; 99: 842–51
  • 24
    Lotze MT, Duncan MA, Gerber LH, Woltering EA, Rosenberg SA. Early versus delayed shoulder motion following axillary dissection: a randomized prospective study. Ann Surg 1981; 193: 288–95
  • 25
    Filippetti M, Santoro E, Graziano F, Petric M, Rinaldi G. Modern therapeutic approaches to postmastectomy brachial lymphedema. Microsurgery 1994; 15: 604–10
    Direct Link:
  • 26
    Jeffrey SS, Goodson WH III, Ikeda DM, Birdwell RL, Bogetz MS. Axillary lymphadenectomy for breast cancer without axillary drainage. Arch Surg 1995; 130: 909–13
  • 27
    Carcoforo P, Soliani G, Maestroni U et al. Octreotide in the treatment of lymphorrhea after axillary node dissection: a prospective randomized controlled trial. J Am Coll Surg 2003; 196: 365–9
  • 28
    Mustonen PK, Harma MA, Eskelinen MJ. The effect of fibrin sealant combined with fibrinolysis inhibitor on reducing the amount of lymphatic leakage after axillary evacuation in breast cancer. A prospective randomized clinical trial. Scand J Surg 2004; 93: 209–12
  • 29
    Capocasale E, Busi N, Valle RD et al. Octreotide in the treatment of lymphorrhea after renal transplantation: a preliminary experience. Transplant Proc 2006; 38: 1047–8
  • 30
    Koch MO, Smith JA Jr. Low molecular weight heparin and radical prostatectomy: a prospective analysis of safety and side effects. Prostate Cancer Prostatic Dis 1997; 1: 101–4
  • 31
    Lundin C, Bersztel A, Wahlberg J, Wadstrom J. Low molecular weight heparin prophylaxis increases the incidence of lymphocele after kidney transplantation. Ups J Med Sci 2002; 107: 9–15
  • 32
    Sieber PR, Rommel FM, Agusta VE et al. Is heparin contraindicated in pelvic lymphadenectomy and radical prostatectomy? J Urol 1997; 158: 869– 71
  • 33
    Tomic R, Granfors T, Sjodin JG, Ohberg L. Lymph leakage after staging pelvic lymphadenectomy for prostatic carcinoma with and without heparin prophylaxis. Scand J Urol Nephrol 1994; 28: 273–5
  • 34
    Weingartner K, Ramaswamy A, Bittinger A, Gerharz EW, Voge D, Riedmiller H. Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic. J Urol 1996; 156: 1969–71
View Full Article (HTML) Get PDF (327K)